Jose Ronaldo Lima de Carvalho Jr. MD , Jin Kyun Oh MD , Sara Ragi BS , Joonpyo Kim PhD , Remy S. Manzi MD , Emily Sun MD , Thiago Cabral MD, PhD , Rubens Belfort Jr. MD, PhD , Vivienne C. Greenstein PhD , Janet R. Sparrow PhD , Stephen H. Tsang MD, PhD
{"title":"BEST1黄斑营养不良的多模态成像和暗适应色度测量:结果测量的确定","authors":"Jose Ronaldo Lima de Carvalho Jr. MD , Jin Kyun Oh MD , Sara Ragi BS , Joonpyo Kim PhD , Remy S. Manzi MD , Emily Sun MD , Thiago Cabral MD, PhD , Rubens Belfort Jr. MD, PhD , Vivienne C. Greenstein PhD , Janet R. Sparrow PhD , Stephen H. Tsang MD, PhD","doi":"10.1016/j.xops.2025.100823","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To characterize longitudinal multimodal imaging characteristics of Best vitelliform macular dystrophy (BVMD) and describe novel outcome measurements for future clinical trials.</div></div><div><h3>Design</h3><div>A single-center retrospective cohort study.</div></div><div><h3>Subjects</h3><div>A total of 36 eyes of 18 patients with genetically and clinically confirmed diagnoses of BVMD were evaluated.</div></div><div><h3>Methods</h3><div>Patients underwent complete ophthalmic examination and multimodal imaging including spectral-domain OCT and short-wavelength autofluorescence. Dark-adapted chromatic (DAC) perimetry was obtained in 8 of 18 patients.</div></div><div><h3>Main Outcome Measures</h3><div>Longitudinal changes in lesion width, area, and measures of retinal thickness, including outer nuclear layer (ONL) thickness, were evaluated as primary outcome measures. The changes were measured at every visit to the ophthalmology clinic, with a difference between the first and most recent individual's visit of 76.56 ± 33.36 months (range 10–123 months), on average. Scotopic sensitivity as measured by DAC perimetry was compared within and outside the lesion.</div></div><div><h3>Results</h3><div>Lesion width increased with progressive disease stage from the vitelliform stage (1.345 ± 0.218 mm) through the vitelliruptive stage (2.913 ± 0.893 mm) before decreasing in the atrophic stage (2.287 ± 0.456 mm). Central macular thickness increased between the vitelliform (0.277 ± 0.132 mm) and the pseudohypopyon stage (0.334 ± 0.055 mm) before decreasing through the vitelliruptive (0.288 ± 0.085 mm) and atrophic stages (0.236 ± 0.020 mm). Measurements of ONL thickness at the temporal and nasal borders of the lesion demonstrated a significant difference over time (<em>P</em> = 0.001). Dark-adapted chromatic perimetry showed significant differences in scotopic sensitivity within the lesion compared with outside the lesion and compared with values for normal control subjects (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>Features of multimodal imaging, including measurements of ONL thickness along the temporal and nasal borders of the lesion, as well as scotopic sensitivity as measured by DAC perimetry, may serve as valuable outcome measurements for treatment trials for BVMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":74363,"journal":{"name":"Ophthalmology science","volume":"5 5","pages":"Article 100823"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multimodal Imaging and Dark-Adapted Chromatic Perimetry in BEST1 Vitelliform Macular Dystrophy: Identification of Outcome Measurements\",\"authors\":\"Jose Ronaldo Lima de Carvalho Jr. MD , Jin Kyun Oh MD , Sara Ragi BS , Joonpyo Kim PhD , Remy S. Manzi MD , Emily Sun MD , Thiago Cabral MD, PhD , Rubens Belfort Jr. MD, PhD , Vivienne C. Greenstein PhD , Janet R. Sparrow PhD , Stephen H. Tsang MD, PhD\",\"doi\":\"10.1016/j.xops.2025.100823\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To characterize longitudinal multimodal imaging characteristics of Best vitelliform macular dystrophy (BVMD) and describe novel outcome measurements for future clinical trials.</div></div><div><h3>Design</h3><div>A single-center retrospective cohort study.</div></div><div><h3>Subjects</h3><div>A total of 36 eyes of 18 patients with genetically and clinically confirmed diagnoses of BVMD were evaluated.</div></div><div><h3>Methods</h3><div>Patients underwent complete ophthalmic examination and multimodal imaging including spectral-domain OCT and short-wavelength autofluorescence. Dark-adapted chromatic (DAC) perimetry was obtained in 8 of 18 patients.</div></div><div><h3>Main Outcome Measures</h3><div>Longitudinal changes in lesion width, area, and measures of retinal thickness, including outer nuclear layer (ONL) thickness, were evaluated as primary outcome measures. The changes were measured at every visit to the ophthalmology clinic, with a difference between the first and most recent individual's visit of 76.56 ± 33.36 months (range 10–123 months), on average. Scotopic sensitivity as measured by DAC perimetry was compared within and outside the lesion.</div></div><div><h3>Results</h3><div>Lesion width increased with progressive disease stage from the vitelliform stage (1.345 ± 0.218 mm) through the vitelliruptive stage (2.913 ± 0.893 mm) before decreasing in the atrophic stage (2.287 ± 0.456 mm). Central macular thickness increased between the vitelliform (0.277 ± 0.132 mm) and the pseudohypopyon stage (0.334 ± 0.055 mm) before decreasing through the vitelliruptive (0.288 ± 0.085 mm) and atrophic stages (0.236 ± 0.020 mm). Measurements of ONL thickness at the temporal and nasal borders of the lesion demonstrated a significant difference over time (<em>P</em> = 0.001). Dark-adapted chromatic perimetry showed significant differences in scotopic sensitivity within the lesion compared with outside the lesion and compared with values for normal control subjects (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>Features of multimodal imaging, including measurements of ONL thickness along the temporal and nasal borders of the lesion, as well as scotopic sensitivity as measured by DAC perimetry, may serve as valuable outcome measurements for treatment trials for BVMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>\",\"PeriodicalId\":74363,\"journal\":{\"name\":\"Ophthalmology science\",\"volume\":\"5 5\",\"pages\":\"Article 100823\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666914525001216\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666914525001216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Multimodal Imaging and Dark-Adapted Chromatic Perimetry in BEST1 Vitelliform Macular Dystrophy: Identification of Outcome Measurements
Objective
To characterize longitudinal multimodal imaging characteristics of Best vitelliform macular dystrophy (BVMD) and describe novel outcome measurements for future clinical trials.
Design
A single-center retrospective cohort study.
Subjects
A total of 36 eyes of 18 patients with genetically and clinically confirmed diagnoses of BVMD were evaluated.
Methods
Patients underwent complete ophthalmic examination and multimodal imaging including spectral-domain OCT and short-wavelength autofluorescence. Dark-adapted chromatic (DAC) perimetry was obtained in 8 of 18 patients.
Main Outcome Measures
Longitudinal changes in lesion width, area, and measures of retinal thickness, including outer nuclear layer (ONL) thickness, were evaluated as primary outcome measures. The changes were measured at every visit to the ophthalmology clinic, with a difference between the first and most recent individual's visit of 76.56 ± 33.36 months (range 10–123 months), on average. Scotopic sensitivity as measured by DAC perimetry was compared within and outside the lesion.
Results
Lesion width increased with progressive disease stage from the vitelliform stage (1.345 ± 0.218 mm) through the vitelliruptive stage (2.913 ± 0.893 mm) before decreasing in the atrophic stage (2.287 ± 0.456 mm). Central macular thickness increased between the vitelliform (0.277 ± 0.132 mm) and the pseudohypopyon stage (0.334 ± 0.055 mm) before decreasing through the vitelliruptive (0.288 ± 0.085 mm) and atrophic stages (0.236 ± 0.020 mm). Measurements of ONL thickness at the temporal and nasal borders of the lesion demonstrated a significant difference over time (P = 0.001). Dark-adapted chromatic perimetry showed significant differences in scotopic sensitivity within the lesion compared with outside the lesion and compared with values for normal control subjects (P < 0.05).
Conclusions
Features of multimodal imaging, including measurements of ONL thickness along the temporal and nasal borders of the lesion, as well as scotopic sensitivity as measured by DAC perimetry, may serve as valuable outcome measurements for treatment trials for BVMD.
Financial Disclosure(s)
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.